Practice 01 · Fundraising strategy and materials

Raise the right amount, from the right investors, with materials that hold up.

We shape the round, build the materials and run the process with you, so every investor conversation starts from a business case rather than a slide count.

Book a 20-minute call What we deliver

Line drawing of a hatchetfish on a square grid, and the same outline on a sheared grid, becoming a related species.

Bring us in when

You are preparing a raise in the next 3 to 6 months
Meetings are happening, but not converting
The deck looks good, but the story still feels thin

What we deliver

Round strategy

How much to raise, on what instrument, and which milestone the round buys.

Investor materials

Send-ahead and meeting decks, a one-pager, an investor FAQ and website copy.

Investor targeting

A tiered list matched on stage, thesis and check size, with warm paths mapped.

Outreach and pipeline

Outreach copy, follow-up sequences and a working investor pipeline.

Meeting and pitch preparation

Mock pitches, a tough-question bank and live pitch feedback.

Diligence readiness

Data room structure, diligence answers, and fluency in valuation and terms.

Typical outputsDeckOne-pagerInvestor listOutreach sequenceData room checklist

Ways to start

Fixed scope, clear deliverables.

Fees are fixed and agreed before we start. We will recommend the right starting point on the intro call.

Pitch Deck Audit

3 to 5 days

A written diagnosis, slide-by-slide commentary and a tiered investor shortlist, walked through together in a working session.

Best for: A deck that exists but is not landing

Investor-Ready Kit

About 3 weeks

The deck rebuilt in send-ahead and meeting versions, a one-pager, outreach copy, an investor list and a mock pitch.

Best for: Raising in the next 3 to 6 months

Strategic Advisory

90 days or more, limited availability

Ongoing work with a small number of companies at a time: strategy sessions, review of materials and models, and meeting preparation.

Best for: Senior counsel through a raise or a deal

Related work

Seed · Women's health therapeutic

Putting the strongest evidence first

A well-protected asset with published preclinical data, a recognized clinical lead and written interest from a pharma company. The deck opened with regulatory detail, and the strongest credibility points arrived near the end.

What changed: The team went into a pitch competition the following week leading with the problem, the data and the partner interest, instead of the regulatory background.

Read the case

Series A · Platform therapeutics

Platform or lead program?

A strong preclinical package, including head-to-head results against standard of care, and well-known early investors. The deck had no ask, no competitive landscape and no exit path, and moved between a broad platform and a single lead indication.

What changed: One coherent story: a lead program investors can underwrite, and a platform that explains why they should stay for the next round.

Read the case

The experience behind this practice

Co-led a bridge and Series A raise as Chief Business and Operating Officer at Concarlo Therapeutics.
Network Partner with a pre-seed and seed fund, and mentor across life science accelerators.

From Bio Founder GPS

May 11, 2026

Before we speak.

Other practices

Where we see a genuine fit, through our network. Introductions are never a paid line item, and we do not take success fees.

Book a 20-minute call

Talk through your situation in 20 minutes.

You'll speak with Vadim Shepel

Founder and Principal, Bench2Bio

01
Where you are
Your stage, your science and what is coming next: a raise, a partner conversation or a decision.
02
What investors or partners will test
An honest read on the gaps that will matter most, even if we never work together.
03
Whether and how we can help
A recommended starting point, or a referral if someone else is a better fit.

Prefer email? vadim@bench2bio.com

Choose a timeOpen in Calendly